Sign in

    James Liberman

    Research Analyst at American Trust Investment Services

    James Bennett Liberman is a registered financial advisor associated with both Chicago Capital Management Advisors, LLC and American Trust Investment Services. While his primary focus is general wealth management rather than sell-side equity analysis, he operates as a financial advisor rather than as a ranked Wall Street analyst and does not publicly publish coverage lists or performance rankings on platforms like TipRanks. Liberman's career experience includes working across multiple advisory firms, and he is an active FINRA-registered professional, offering investment management and customized financial solutions to clients. He maintains all necessary professional credentials for securities advising, including compliance with regulatory standards.

    James Liberman's questions to VICOR (VICR) leadership

    James Liberman's questions to VICOR (VICR) leadership • Q2 2025

    Question

    James Liberman requested more color on the outlook for Vicor's automotive business, particularly regarding recent customer audits and market development.

    Answer

    Corporate VP Philip Davies described the automotive market entry as a 'hard slog' requiring a gradual ramp, starting with lower-volume programs. He confirmed Vicor is passing critical audit phases with European and ASEAN OEMs, which is a key step. Davies noted that while activity is exciting, significant revenue contribution from automotive is still further out, likely in the 2029-2030 timeframe.

    Ask Fintool Equity Research AI

    James Liberman's questions to VICOR (VICR) leadership • Q1 2025

    Question

    James Liberman asked about the status, timeline, and process of Vicor's appeal to the Federal Circuit concerning the Foxconn license.

    Answer

    CEO Patrizio Vinciarelli expressed strong confidence in Vicor's position in the appeal, noting that both an administrative law judge and a district court judge had previously found that Foxconn has no license. He stated the company believes the commission's contrary finding can be overcome and also downplayed the issue's long-term impact, as it relates to only one patent within Vicor's extensive portfolio.

    Ask Fintool Equity Research AI

    James Liberman's questions to NANX leadership

    James Liberman's questions to NANX leadership • Q4 2024

    Question

    Asked for details on the two new plant-based patents, the nature of the award-winning Au Lait Face Milk product, whether inventory turns would provide enough cash for growth, and if the BASF relationship could help mitigate potential tariff impacts in Europe.

    Answer

    The patents are for a novel plant-based antioxidant and a skin-soothing agent delivery system. The Au Lait Face Milk is a 'white label' formula developed by Solesence, available for brands to license. Improving working capital management is a key goal for 2025 to manage cash flow. It is too early to tell if the BASF relationship will help with tariffs in Europe.

    Ask Fintool Equity Research AI